{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kopylov AT"],"funding":["Russian Science Foundation"],"pagination":["2139"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9901842"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["Despite of multiple systematic studies of schizophrenia based on proteomics, metabolomics, and genome-wide significant loci, reconstruction of underlying mechanism is still a challenging task. Combination of the advanced data for quantitative proteomics, metabolomics, and genome-wide association study (GWAS) can enhance the current fundamental knowledge about molecular pathogenesis of schizophrenia. In this study, we utilized quantitative proteomic and metabolomic assay, and high throughput genotyping for the GWAS study. We identified 20 differently expressed proteins that were validated on an independent cohort of patients with schizophrenia, including ALS, A1AG1, PEDF, VTDB, CERU, APOB, APOH, FASN, GPX3, etc. and almost half of them are new for schizophrenia. The metabolomic survey revea"],"journal":["Scientific reports"],"pubmed_title":["Consolidation of metabolomic, proteomic, and GWAS data in connective model of schizophrenia."],"pmcid":["PMC9901842"],"funding_grant_id":["75-15-2022-305"],"pubmed_authors":["Kaysheva AL","Stepanov AA","Malsagova KA","Elmuratov AU","Kostyuk GP","Zakharova NV","Butkova TV","Kopylov AT"],"additional_accession":[]},"is_claimable":false,"name":"Consolidation of metabolomic, proteomic, and GWAS data in connective model of schizophrenia.","description":"Despite of multiple systematic studies of schizophrenia based on proteomics, metabolomics, and genome-wide significant loci, reconstruction of underlying mechanism is still a challenging task. Combination of the advanced data for quantitative proteomics, metabolomics, and genome-wide association study (GWAS) can enhance the current fundamental knowledge about molecular pathogenesis of schizophrenia. In this study, we utilized quantitative proteomic and metabolomic assay, and high throughput genotyping for the GWAS study. We identified 20 differently expressed proteins that were validated on an independent cohort of patients with schizophrenia, including ALS, A1AG1, PEDF, VTDB, CERU, APOB, APOH, FASN, GPX3, etc. and almost half of them are new for schizophrenia. The metabolomic survey revea","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-07-14T22:30:35.751Z","creation":"2025-02-19T00:12:11.963Z"},"accession":"S-EPMC9901842","cross_references":{"pubmed":["36747015"],"doi":["10.1038/s41598-023-29117-7"]}}